Shots:

• The companies signed an agreement to ensure non-exclusive commercial access to Thermo Fisher’s Gibco CTS Dynabeads CD3/CD28
• The focus of the agreement is to support clinical development & commercial manufacturing of leading CAR-T therapies in China including JW’s relmacabtagene autoleucel (relma-cel)
• Relma-cel is an anti-CD19 CAR-T therapy for 3L treatment for r/r B-cell lymphoma and is expected to be first CAR-T therapy to be approved as a Category 1 biologics in China. Additionally- NMPA has accepted the NDA of Relma-cel

 ­ Ref: PRNewswire | Image: The Spruce